ArticleScientific reports2025
Astaxanthin mitigates cardiac toxicity induced via doxorubicin by alleviating mitochondrial fission and autophagy in rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nutritional Prevention of Oxidative Stress-Induced Cardiotoxicity in Pediatric Cardio-Oncology: Molecular Mechanisms and Translational Perspectives-A Narrative Review.International journal of molecular sciences · 2026Review
- Astaxanthin attenuates CTX-induced premature ovarian failure by alleviating ovarian apoptosis and autophagy in vivo.Journal of ovarian research · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Doxorubicin (DOX)-induced cardiotoxicity is the most prevalent adverse reaction of DOX during chemotherapy and significantly impacts its clinical application. At present, clinical interventions for mitigating DOX-induced cardiotoxicity remain sub-optimal. Mitochondria are the primary target organ of DOX-induced cardiotoxicity, which can result in cardiac mitochondrial dynamic imbalance and impaired mitochondrial autophagy. Astaxanthin (ASTA) is an antioxidant that exerts cardioprotective effects in various cardiac diseases. Meanwhile, it can also ameliorate mitochondrial dynamic dysregulation and suppress the abnormal activation of autophagy. Therefore, ASTA was administered to a rat model of DOX-induced cardiotoxicity, and its cardioprotective effects were observed. Additionally, the mechanisms underlying its cardioprotective effects were investigated by detecting proteins related to mitochondrial dynamics and mitophagy. The results revealed that ASTA up-regulated the expression of mitochondrial fusion protein 2(Mfn2) and Optic Atrophy 1(OPA1), reduced the expression level of dynamin-related protein 1 (Drp1) and Fission 1 Protein(Fis-1), and regulated PTEN-Induced Putative Kinase 1(PINK1)/ Parkin RBR E3 Ubiquitin Protein Ligase (Parkin)-mediated mitochondrial autophagy to alleviate mitochondrial damage in the rat model. Consequently, we hypothesize that ASTA alleviates DOX-induced cardiotoxicity by regulating mitochondrial dynamic imbalance and mitophagy, thereby attenuating mitochondrial damage and exerting cardioprotective effects. Overall, these findings indicate that ASTA holds promise as a prospective drug for ameliorating DOX-induced cardiotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.